Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E26.71 EPS (ttm)18.47 Insider Own19.90% Shs Outstand111.23M Perf Week9.74%
Market Cap54.87B Forward P/E16.32 EPS next Y30.22 Insider Trans-1.86% Shs Float81.81M Perf Month1.05%
Income2.12B PEG3.06 EPS next Q6.32 Inst Own73.60% Short Float3.13% Perf Quarter33.63%
Sales7.86B P/S6.98 EPS this Y-10.80% Inst Trans-0.15% Short Ratio1.98 Perf Half Y75.73%
Book/sh101.55 P/B4.86 EPS next Y10.50% ROA15.50% Target Price476.21 Perf Year21.35%
Cash/sh28.90 P/C17.07 EPS next 5Y8.72% ROE20.70% 52W Range271.37 - 518.00 Perf YTD31.38%
Dividend- P/FCF27.43 EPS past 5Y44.00% ROI16.10% 52W High-4.76% Beta0.51
Dividend %- Quick Ratio3.20 Sales past 5Y22.80% Gross Margin90.10% 52W Low81.79% ATR31.90
Employees8100 Current Ratio3.70 Sales Q/Q12.50% Oper. Margin28.10% RSI (14)59.14 Volatility4.50% 7.41%
OptionableYes Debt/Eq0.06 EPS Q/Q4.00% Profit Margin26.90% Rel Volume0.90 Prev Close498.75
ShortableYes LT Debt/Eq0.06 EarningsMay 07 BMO Payout0.00% Avg Volume1.29M Price493.32
Recom2.10 SMA205.58% SMA5015.89% SMA20041.87% Volume1,159,028 Change-1.09%
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $530
Feb-26-20Upgrade Canaccord Genuity Hold → Buy $550
Feb-26-20Downgrade Robert W. Baird Outperform → Neutral $410
Feb-25-20Upgrade Jefferies Hold → Buy $355 → $492
Feb-11-20Upgrade Argus Hold → Buy $430
Dec-24-19Initiated Raymond James Mkt Perform
Dec-16-19Downgrade Evercore ISI Outperform → In-line
Dec-13-19Upgrade Credit Suisse Neutral → Outperform $400
Nov-12-19Initiated SunTrust Hold $360
Nov-07-19Upgrade Citigroup Neutral → Buy $340 → $420
Oct-17-19Resumed BofA/Merrill Neutral $325
Sep-23-19Upgrade Guggenheim Neutral → Buy $355 → $403
Aug-07-19Upgrade Robert W. Baird Neutral → Outperform $410
Jun-18-19Downgrade Argus Buy → Hold
May-23-19Resumed Citigroup Neutral
May-21-19Initiated Credit Suisse Neutral $336
May-08-19Reiterated Canaccord Genuity Hold $408 → $353
Jan-04-19Upgrade Guggenheim Neutral → Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $415
Apr-05-20 10:22AM  Theres scant evidence so far for chloroquine as a COVID-19 drug but theres already a shortage MarketWatch
Apr-03-20 01:44PM  REGN, MAR, CWH, TRWH and MANU as Zacks Bull and Bear of the Day Zacks
10:37AM  The Best and Worst-Performing S&P 500 Stocks of the 1st Quarter GuruFocus.com
09:48AM  Incyte to Evaluate Lead Drug Jakafi for COVID-19 Infection Zacks
07:48AM  5 Top Momentum Stocks for April Amid Coronavirus-Led Turmoil (Revised) Zacks
05:00AM  Bull of the Day: Regeneron Pharmaceuticals, Inc. (REGN) Zacks
02:42AM  Mesoblast's (MESO) BLA for Ryoncil Gets FDA Priority Review Zacks
02:39AM  RPT-Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19 Reuters
01:14AM  Sanofi and Regeneron's Dupixent shows more encouraging results Reuters
12:59AM  Dupixent® (dupilumab) Phase 3 Data at Revolutionizing Atopic Dermatitis Conference Show Significant Improvement in Severe Atopic Dermatitis for Children Aged 6 to 11 Years PR Newswire
Apr-02-20 04:19PM  Recovering From the Coma GuruFocus.com
12:19PM  The Zacks Analyst Blog Highlights: Regeneron, Netflix, Clorox, NVIDIA and SBA Zacks
12:13PM  The Zacks Analyst Blog Highlights: Moderna, Regeneron, Zoom Video, Netflix and Peloton Zacks
10:15AM  Healthcare stocks show their defensive allure in ailing market Reuters
Apr-01-20 02:33PM  Regeneron making 500,000 coronavirus test kits in East Greenbush American City Business Journals
12:14PM  The Zacks Analyst Blog Highlights: Grocery Outlet, Sprouts Farmers, PLDT, Regeneron and Clorox Zacks
11:42AM  S&P Sees Worst-Ever Q1: 5 Stocks That Gained in the ETF Zacks
08:21AM  Top Stock Trades to Beat Coronavirus Blues in April Zacks
08:16AM  6 Top S&P 500 Stocks That Have Surged Despite Worst-Ever Q1 Zacks
06:37AM  These 30 S&P 500 stocks actually rose during the disastrous first quarter MarketWatch
06:10AM  These 19 companies are working on coronavirus treatments or vaccines heres where things stand MarketWatch
Mar-31-20 02:18PM  8 Experimental Coronavirus Treatments to Watch Barrons.com
10:51AM  Gilead Expands Access to Experimental Coronavirus Treatment Zacks
09:48AM  Company News for Mar 31, 2020 Zacks
07:41AM  5 Top Momentum Stocks for April Amid Coronavirus-Led Turmoil Zacks
Mar-30-20 04:27PM  Dow books nearly 700-point gain as investors eye efforts to slow coronavirus spread MarketWatch +5.22%
01:58PM  Coronavirus update: 755,591 cases world-wide, 36,211 deaths; Italy, Spain and New York City struggle to cope MarketWatch
11:48AM  The 3 Strongest Stocks in the S&P 500 Investopedia
11:46AM  Regeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol PR Newswire
11:39AM  Sanofi Begins Kevzara Study for Severe Coronavirus Infection Zacks
11:30AM  Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year? Zacks
09:04AM  Regeneron and Sanofi Treat First Person Outside U.S. in Coronavirus-Drug Trial TheStreet.com
08:00AM  First patient treated in Regeneron, Sanofi trial for COVID-19 treatment MarketWatch
06:00AM  Regeneron Merits a Premium Valuation MoneyShow
01:29AM  Sanofi, Regeneron expand testing of potential coronavirus treatment Reuters
01:00AM  Sanofi, Regeneron expand testing of potential coronavirus treatment Reuters
12:59AM  First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19 PR Newswire
Mar-29-20 07:42AM  2 Biotech Stocks in the Hunt for New Coronavirus Drugs; Oppenheimer Weighs In TipRanks
Mar-27-20 03:05PM  Dow Jones Smacked Lower After Historic Run: 5 Coronavirus Stocks On The Move Investor's Business Daily
12:59PM  The Easy Gains May Be Over for American Airlines Stock InvestorPlace
12:02PM  Regeneron Holds Firm After Breakout Investor's Business Daily Video
10:44AM  Dow Jones Dives After Historic 3-Day Surge Investor's Business Daily Video
10:04AM  UC Davis conducting clinical trials of two drugs to treat COVID-19 American City Business Journals
08:15AM  10 Stocks To Buy With Low Debt And High Liquidity Benzinga
Mar-26-20 08:27PM  The 5 Best Stocks (And 5 Worst) of the Coronavirus Correction Kiplinger +5.24%
06:16PM  Gilead Asks FDA to Withdraw Orphan Drug Tag for Remdesivir Zacks
03:47PM  UnitedHealth Group rolls out coronavirus testing kits Yahoo Finance Video
02:53PM  The Top 10 Biotechnology Companies Investopedia
10:52AM  Biotech Stocks Accelerate Efforts for Coronavirus Treatments Zacks
10:16AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals Zacks
Mar-25-20 12:33PM  Top 5 Drug Stocks To Stop The Coronavirus Pandemic Zacks
11:34AM  Coronavirus Drug Development Race to Boost These 4 Stocks Zacks
08:16AM  US Government Reaches Deal on Stimulus Package: 5 Top Picks Zacks
Mar-24-20 05:45PM  Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know Zacks
10:19AM  3 Biotech Stocks Fighting the Coronavirus; Heres What to Expect TipRanks
09:52AM  Top Ranked Momentum Stocks to Buy for March 24th Zacks
07:39AM  The Zacks Analyst Blog Highlights: Calix, CBIZ, The Ensign Group, Regeneron Pharmaceuticals and Turning Point Brands Zacks
Mar-23-20 09:22AM  Top Ranked Momentum Stocks to Buy for March 23rd Zacks
08:09AM  Market is Wavering! Buy 5 Best Low-Volatility Stocks Now Zacks
Mar-22-20 10:13AM  Trump makes the case for chloroquine as a COVID-19 treatment, though it has not been approved by the FDA for this illness MarketWatch
Mar-20-20 10:52AM  Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates Zacks -10.49%
Mar-19-20 06:56PM  Coronavirus Stock Market Crash: Profiting In The Next Uptrend By Using Past Bear Markets Investor's Business Daily
06:40PM  The 12 Best Low-Volatility Stocks of the Market Crash Kiplinger
03:02PM  President Trump Praises Antiviral Treatments in FDA News Conference Barrons.com
10:39AM  The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals Zacks
09:56AM  Roche to Evaluate Actemra for Severe COVID-19 Pneumonia Zacks
09:49AM  5 Low-Beta Stocks to Tackle Coronavirus-Led Market Volatility Zacks
08:26AM  Drugs or Vaccines: Which Will Be More Crucial Against Coronavirus? Zacks
07:58AM  Coronavirus update: 194,217 cases, 7,864 deaths, COVID-19 clinical trials begin in the U.S. MarketWatch
07:00AM  Two generic drugs being tested in U.S. in race to find coronavirus treatments Reuters
06:00AM  A Watch List to Nibble On MoneyShow
Mar-18-20 05:49PM  Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More Zacks
05:45PM  Regeneron (REGN) Stock Moves -1.36%: What You Should Know Zacks
04:24PM  Pharmaceutical Companies Gain in the Fight Against Covid-19 GuruFocus.com
11:35AM  Merck's Chronic Cough Candidate Achieves Goals in Phase III Zacks
11:30AM  The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA Zacks
10:57AM  Pfizer, Regeneron Give Update on Coronavirus Drug Development Zacks
10:43AM  Hopes of a COVID-19 Vaccine Buoy Drug Makers: 3 Solid Buys Zacks
10:27AM  Regeneron Up on Identification of Antibodies for Coronavirus Zacks
10:20AM  COVID-19 vaccine developer takes key step toward coronavirus trial in early summer American City Business Journals
10:15AM  5 Stocks in the S&P 500 ETF Still Up YTD Zacks
09:46AM  Regeneron Pharmaceuticals Could Be a Bright Spot in a Sea of Declines TheStreet.com
09:36AM  Why Regeneron (REGN) Stock Might be a Great Pick Zacks
09:30AM  Company News for Mar 18, 2020 Zacks
09:10AM  Abeona Treats First Patient in Pivotal Gene Therapy Study Zacks
08:45AM  Think twice before investing in biotech companies working on coronavirus treatments the odds of picking a winner are low MarketWatch
08:28AM  Heres one analysts take on the coronavirus drugs for today and the future MarketWatch
03:48AM  Regeneron Makes Progress in Antibody Program to Treat Coronavirus Pandemic TipRanks
Mar-17-20 06:09PM  US STOCKS-Wall St jumps after Monday's historic sell-off as Fed boosts liquidity to fight coronavirus effect Reuters +11.54%
05:37PM  The Dow Surged 1,049 Points Because the Fed and the Treasury Can Beat Back a Recession Barrons.com
04:37PM  This IBD Stock Of The Day Plans To Test A Coronavirus Drug This Summer Investor's Business Daily
02:26PM  Regenerons CEO Says We Could Have a Covid-19 Treatment Quickly Barrons.com
01:00PM  The Magic Mice of Regeneron TheStreet.com
12:44PM  US STOCKS-Wall St rebounds from Monday's crash as Fed boosts liquidity Reuters
12:08PM  Stocks Off Session Lows As This Sector Comes Into Focus In Coronavirus Crisis Investor's Business Daily
11:45AM  Dow Jones Gains 600 Points As Coronavirus Stock Market Correction Continues; Amazon, McDonald's, Regeneron In Focus Investor's Business Daily
11:40AM  Campbell Soup Providing Comfort Investor's Business Daily Video
11:33AM  Lilly's Olumiant Gets Breakthrough Therapy Tag for Hair Loss Zacks
11:17AM  Regeneron/Sanofi to Test Kevzara for Severe Coronavirus Infection Zacks
11:15AM  A Coronavirus Treatment Worth Watching Bloomberg
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services for the development of new treatments combating the coronavirus. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Landry Robert EEVP Finance CFOApr 03Sale494.28683337,59224,373Apr 03 04:50 PM
Landry Robert EEVP Finance CFOApr 02Option Exercise272.703,000818,10028,726Apr 03 04:49 PM
Landry Robert EEVP Finance CFOApr 02Sale495.8810552,06825,056Apr 03 04:50 PM
Landry Robert EEVP Finance CFOApr 02Sale489.321,248610,67225,161Apr 03 04:49 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 02Sale489.986,7973,330,40614,438Apr 03 04:08 PM
Fenimore Christopher R.VP ControllerApr 01Option Exercise30.631,20036,75614,297Apr 03 04:05 PM
Landry Robert EEVP Finance CFOApr 01Option Exercise272.706,0001,636,20026,937Apr 03 04:49 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 01Option Exercise59.2015,000888,00023,924Apr 03 04:08 PM
Landry Robert EEVP Finance CFOApr 01Sale488.02600292,81124,373Apr 03 04:49 PM
Fenimore Christopher R.VP ControllerApr 01Sale488.411,200586,09613,097Apr 03 04:05 PM
RYAN ARTHUR FDirectorApr 01Sale483.8510048,38528,943Apr 01 06:49 PM
RYAN ARTHUR FDirectorMar 30Sale466.6910046,66929,043Apr 01 06:49 PM
YANCOPOULOS GEORGEPresident and Chief ScientificMar 10Sale470.47117,81555,428,041517,799Mar 11 04:05 PM
YANCOPOULOS GEORGEPresident and Chief ScientificMar 09Option Exercise30.63246,7367,557,524713,990Mar 11 04:05 PM
GOLDSTEIN JOSEPH LDirectorMar 09Option Exercise33.422,00066,84011,643Mar 10 04:05 PM
GOLDSTEIN JOSEPH LDirectorMar 09Sale475.842,000951,6849,643Mar 10 04:05 PM
STAHL NEILEVP Research and DevelopmentFeb 27Sale452.2610,3494,680,46011,380Feb 28 04:40 PM
SING GEORGE LDirectorFeb 26Option Exercise33.422,50083,550117,915Feb 28 04:30 PM
STAHL NEILEVP Research and DevelopmentFeb 26Option Exercise52.0325,0001,300,75036,380Feb 28 04:40 PM
SING GEORGE LDirectorFeb 26Sale452.832,4001,086,8002,400Feb 28 04:30 PM
SING GEORGE LDirectorFeb 26Sale460.002,5001,150,000115,415Feb 28 04:30 PM
Landry Robert EEVP Finance CFOFeb 26Sale456.2120091,24224,973Feb 26 06:14 PM
Van Plew Daniel PEVP & General Mgr Industrial OFeb 26Sale457.2315,6427,152,01628,251Feb 27 04:12 PM
Landry Robert EEVP Finance CFOFeb 25Option Exercise272.701,000272,70026,187Feb 26 06:14 PM
Van Plew Daniel PEVP & General Mgr Industrial OFeb 25Option Exercise30.6332,7351,002,67360,986Feb 27 04:12 PM
Landry Robert EEVP Finance CFOFeb 25Sale449.0121496,08825,173Feb 26 06:14 PM
Landry Robert EEVP Finance CFOFeb 24Option Exercise272.701,000272,70025,973Feb 26 06:14 PM
BROWN MICHAEL SDirectorFeb 24Option Exercise273.672,000547,3402,643Feb 25 04:03 PM
YANCOPOULOS GEORGEPresident and Chief ScientificFeb 24Sale420.17118,12349,631,741517,799Feb 25 04:05 PM
BROWN MICHAEL SDirectorFeb 24Sale419.002,000838,001643Feb 25 04:03 PM
Tessier-Lavigne MarcDirectorFeb 13Option Exercise53.0814,279757,94411,109Feb 14 04:10 PM
Tessier-Lavigne MarcDirectorFeb 13Sale400.0114,2795,711,7111,830Feb 14 04:10 PM
Landry Robert EEVP Finance CFOFeb 13Sale400.0510742,80624,973Feb 14 04:10 PM
Landry Robert EEVP Finance CFOFeb 12Option Exercise272.70500136,35025,473Feb 14 04:10 PM
GOLDSTEIN JOSEPH LDirectorFeb 07Sale382.831,000382,8309,643Feb 10 04:45 PM
MURPHY ANDREW JEVP ResearchJan 27Sale340.918,0002,727,27949,951Jan 28 05:06 PM
Fenimore Christopher R.VP ControllerJan 24Option Exercise30.6350015,31513,097Jan 27 04:04 PM
SING GEORGE LDirectorJan 02Option Exercise24.4115,000366,150130,095Jan 06 04:02 PM
SING GEORGE LDirectorJan 02Sale371.9815,0005,579,700115,095Jan 06 04:02 PM
Fenimore Christopher R.VP ControllerDec 20Option Exercise30.6340012,25212,597Dec 23 04:02 PM
BROWN MICHAEL SDirectorDec 13Option Exercise273.674,0001,094,6804,323Dec 13 04:07 PM
Fenimore Christopher R.VP ControllerDec 13Sale376.141,682632,66512,197Dec 13 06:03 PM
BROWN MICHAEL SDirectorDec 13Sale373.994,0001,495,968323Dec 13 04:07 PM
VAGELOS P ROYChairman of the BoardDec 13Sale376.0451,84219,494,489304,485Dec 13 05:43 PM
VAGELOS P ROYChairman of the BoardDec 12Option Exercise21.25107,6552,287,669412,140Dec 13 05:43 PM
YANCOPOULOS GEORGEPresident and CSODec 12Option Exercise21.25245,2955,212,519521,876Dec 13 04:44 PM
Fenimore Christopher R.VP ControllerDec 12Option Exercise52.033,100161,29315,297Dec 13 06:03 PM
SCHLEIFER LEONARD SPresident & CEODec 12Option Exercise21.25312,4006,638,500571,708Dec 13 04:05 PM
GOLDSTEIN JOSEPH LDirectorNov 27Option Exercise33.421,00033,42011,323Dec 02 04:03 PM
GOLDSTEIN JOSEPH LDirectorNov 27Sale370.001,000370,00010,323Dec 02 04:03 PM
STAHL NEILEVP Research and DevelopmentNov 26Sale364.074,0061,458,46722,455Nov 26 04:29 PM
STAHL NEILEVP Research and DevelopmentNov 25Option Exercise52.0310,000520,30032,455Nov 26 04:29 PM
VAGELOS P ROYChairman of the BoardNov 25Sale363.8722,1498,059,412304,485Nov 26 04:02 PM
GOLDSTEIN JOSEPH LDirectorNov 22Option Exercise33.421,00033,42011,323Nov 22 04:07 PM
VAGELOS P ROYChairman of the BoardNov 22Option Exercise21.2546,138980,433386,716Nov 26 04:02 PM
GOLDSTEIN JOSEPH LDirectorNov 22Sale360.001,000360,00010,323Nov 22 04:07 PM
GOLDSTEIN JOSEPH LDirectorNov 21Option Exercise33.421,00033,42011,323Nov 22 04:07 PM
GOLDSTEIN JOSEPH LDirectorNov 21Sale350.001,000350,00010,323Nov 22 04:07 PM
BROWN MICHAEL SDirectorNov 12Option Exercise273.674,5001,231,5154,823Nov 13 04:11 PM
BROWN MICHAEL SDirectorNov 12Sale349.004,5001,570,500323Nov 13 04:11 PM
GOLDSTEIN JOSEPH LDirectorNov 08Sale340.441,000340,44010,323Nov 08 05:02 PM
STAHL NEILEVP Research and DevelopmentNov 08Sale338.527,3642,492,88822,455Nov 12 04:05 PM
VAGELOS P ROYChairman of the BoardMay 24Option Exercise21.25153,7923,268,080468,669May 29 04:16 PM
GOLDSTEIN JOSEPH LDirectorMay 15Sale305.931,000305,93011,323May 15 08:42 PM
STAHL NEILEVP Research and DevelopmentMay 14Sale305.749,8533,012,48322,450May 15 04:02 PM
STAHL NEILEVP Research and DevelopmentMay 13Option Exercise52.0325,0001,300,75047,450May 15 04:02 PM
Fenimore Christopher R.VP ControllerApr 18Option Exercise21.253507,4387,446Apr 18 07:04 PM